The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Experimental and Clinical Treatment of Chagas Disease: A Review
Open accessAbstract
Chagas disease (CD) is caused by the protozoan parasite Trypanosoma cruzi that infects a broad range of triatomines and mammalian species, including man. It afflicts 8 million people in Latin America, and its incidence is increasing in nonendemic countries owing to rising international immigration and nonvectorial transmission routes such as blood donation. Since the 1960s, the only drugs available for the clinical treatment of this infection have been benznidazole (BZ) and nifurtimox (NFX). Treatment with these trypanocidal drugs is recommended in both the acute and chronic phases of CD. These drugs have low cure rates mainly during the chronic phase, in addition both drugs present side effects that may result in the interruption of the treatment. Thus, more efficient and better-tolerated new drugs or pharmaceutical formulations containing BZ or NFX are urgently needed. Here, we review the drugs currently used for CD chemotherapy, ongoing clinical assays, and most-promising new experimental drugs. In addition, the mechanism of action of the commercially available drugs, NFX and BZ, the biodistribution of the latter, and the potential for novel formulations of BZ based on nanotechnology are discussed. Taken together, the literature emphasizes the urgent need for new therapies for acute and chronic CD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
J Antimicrob Chemother 1994; 33: 350–351
O'SHAUGHNESSY, E. M., & DAS, S. S. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/33.2.350 · Cited by 3,746
Rassi, A., Rassi, A., & Marin-Neto, J. A. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60061-x · Cited by 2,119
Randomized Trial of Benznidazole for Chronic Chagas’ Cardiomyopathy
Morillo, C. A., Marin-Neto, J. A., Avezum, A., Sosa-Estani, S., Rassi, A., Rosas, F., Villena, E., Quiroz, R., Bonilla, R., Britto, C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507574 · Cited by 1,014
A Critical Review on Chagas Disease Chemotherapy
Coura, J. R., & Castro, S. L. D. (2002) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/s0074-02762002000100001 · Cited by 1,003
METABOLISM AND FUNCTIONS OF TRYPANOTHIONE IN THE KINETOPLASTIDA
Fairlamb, A. H., & Cerami, A. (1992) · Annual Review of Microbiology · doi:10.1146/annurev.mi.46.100192.003403 · Cited by 768
Randomized Trial of Posaconazole and Benznidazole for Chronic Chagas' Disease
Molina, I., Gómez i Prat, J., Salvador, F., Treviño, B., Sulleiro, E., Serre, N., Pou, D., Roure, S., Cabezos, J., Valerio, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313122 · Cited by 604
Self-citationViotti, R., Vigliano, C., Lococo, B., Bertocchi, G., Petti, M., Alvarez, M. G., Postan, M., & Armenti, A. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00006 · Cited by 598
Specific chemotherapy of Chagas disease: controversies and advances
Urbina, J. A., & Docampo, R. (2003) · Trends in Parasitology · doi:10.1016/j.pt.2003.09.001 · Cited by 567
Filardi, L. S., & Brener, Z. (1987) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/0035-9203(87)90020-4 · Cited by 549
Innovative lead discovery strategies for tropical diseases
Nwaka, S., & Hudson, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2144 · Cited by 521
Specific chemotherapy of Chagas disease: Relevance, current limitations and new approaches
Urbina, J. A. (2010) · Acta Tropica · doi:10.1016/j.actatropica.2009.10.023 · Cited by 473
A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes
Wilkinson, S. R., Taylor, M. C., Horn, D., Kelly, J. M., & Cheeseman, I. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711014105 · Cited by 457
Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness
Khare, S., Nagle, A. S., Biggart, A., Lai, Y. H., Liang, F., Davis, L. C., Barnes, S. W., Mathison, C. J. N., Myburgh, E., Gao, M.-Y., et al. (2016) · Nature · doi:10.1038/nature19339 · Cited by 407
Cysteine Protease Inhibitors Cure an Experimental Trypanosoma cruzi Infection
Engel, J. C., Doyle, P. S., Hsieh, I., & McKerrow, J. H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.4.725 · Cited by 392
Maya, J. D., Cassels, B. K., Iturriaga-Vásquez, P., Ferreira, J., Faúndez, M., Galanti, N., Ferreira, A., & Morello, A. (2007) · Comparative Biochemistry and Physiology Part A: Molecular & Integrative Physiology · doi:10.1016/j.cbpa.2006.03.004 · Cited by 359
In vitro and in vivo experimental models for drug screening and development for Chagas disease
Romanha, A. J., Castro, S. L. D., Soeiro, M. D. N. C., Lannes-Vieira, J., Ribeiro, I., Talvani, A., Bourdin, B., Blum, B., Olivieri, B., Zani, C., et al. (2010) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/s0074-02762010000200022 · Cited by 356
Tissue Tropism of Different Trypanosoma cruzi Strains
Melo, R. C., & Brener, Z. (1978) · The Journal of Parasitology · doi:10.2307/3279787 · Cited by 282
Trypanocidal drugs: mechanisms, resistance and new targets
Wilkinson, S. R., & Kelly, J. M. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001252 · Cited by 240
Ergosterol biosynthesis and drug development for Chagas disease
Urbina, J. A. (2009) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/s0074-02762009000900041 · Cited by 234
Andrade, J. P. D., Marin Neto, J. A., Paola, A. A. V. D., Vilas-Boas, F., Oliveira, G. M. M., Bacal, F., Bocchi, E. A., Almeida, D. R., Fragata Filho, A. A., Moreira, M. D. C. V., et al. (2011) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2011000600002 · Cited by 232
Immune system recognition of Trypanosoma cruzi
Tarleton, R. L. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.06.003 · Cited by 218
Bond, C. S., Zhang, Y., Berriman, M., Cunningham, M. L., Fairlamb, A. H., & Hunter, W. N. (1999) · Structure · doi:10.1016/s0969-2126(99)80011-2 · Cited by 209
Amiodarone Has Intrinsic Anti-Trypanosoma cruzi Activity and Acts Synergistically with Posaconazole
Benaim, G., Sanders, J. M., Garcia-Marchán, Y., Colina, C., Lira, R., Caldera, A. R., Payares, G., Sanoja, C., Burgos, J. M., Leon-Rossell, A., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050691f · Cited by 185
Fexinidazole: A Potential New Drug Candidate for Chagas Disease
Bahia, M. T., Andrade, I. M. D., Martins, T. A. F., Nascimento, Á. F. D. S. D., Diniz, L. D. F., Caldas, I. S., Talvani, A., Trunz, B. B., Torreele, E., & Ribeiro, I. (2012) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0001870 · Cited by 183
Yun, O., Lima, M. A., Ellman, T., Chambi, W., Castillo, S., Flevaud, L., Roddy, P., Parreño, F., Albajar Viñas, P., & Palma, P. P. (2009) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0000488 · Cited by 176
Barr, S. C., Warner, K. L., Kornreic, B. G., Piscitelli, J., Wolfe, A., Benet, L., & McKerrow, J. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.12.5160-5161.2005 · Cited by 170
Urbina, J. A., Payares, G., Sanoja, C., Lira, R., & Romanha, A. J. (2003) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(02)00273-x · Cited by 167
An update on the management of Chagas cardiomyopathy
Rocha, M. O., Teixeira, M. M., & Ribeiro, A. L. (2007) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.5.4.727 · Cited by 158
An overview of Chagas disease treatment
Jannin, J. G., & Villa, L. (2007) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/s0074-02762007005000106 · Cited by 134
Trypanocidal Activity of Nitroaromatic Prodrugs: Current Treatments and Future Perspectives
Wilkinson, S. R., Bot, C., Kelly, J. M., & Hall, B. S. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611796575894 · Cited by 133
Soeiro, M. N. C., Werbovetz, K. A., Boykin, D. W., Wilson, W. D., Wang, M. Z., & Hemphill, A. F. (2013) · Parasitology · doi:10.1017/s0031182013000292 · Cited by 128
Elimination of Chagas disease transmission: perspectives
Dias, J. C. P. (2009) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/s0074-02762009000900007 · Cited by 123
Human antiprotozoal therapy: past, present, and future
Khaw, M. J., & Panosian, C. B. (1995) · Clinical Microbiology Reviews · doi:10.1128/cmr.8.3.427 · Cited by 122
Benznidazole Biotransformation and Multiple Targets in Trypanosoma cruzi Revealed by Metabolomics
Trochine, A., Creek, D. J., Faral‐Tello, P., Barrett, M. P., & Robello, C. (2014) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0002844 · Cited by 121
Chagas disease cardiomyopathy: current concepts of an old disease
Bilate, A. M. B., & Cunha‐Neto, E. (2008) · Revista do Instituto de Medicina Tropical de São Paulo · doi:10.1590/s0036-46652008000200001 · Cited by 107
In Vitro and In Vivo Studies of the Trypanocidal Properties of WRR-483 against Trypanosoma cruzi
Chen, Y., Brinen, L. S., Kerr, I. D., Hansell, E. J., Doyle, P. S., McKerrow, J. H., & Roush, W. R. (2010) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0000825 · Cited by 107
Trypanosoma cruzi: Interaction with vertebrate cells in vitro
Dvorak, J. A., & Hyde, T. P. (1973) · Experimental Parasitology · doi:10.1016/0014-4894(73)90087-8 · Cited by 98
Diniz, L. D. F., Caldas, I. S., Guedes, P. M. D. M., Crepalde, G. P., de Lana, M., Carneiro, C. M., Talvani, A., Urbina, J. A., & Bahia, M. T. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01742-09 · Cited by 98
Self-citationBrachwitz, H., & Vollgraf, C. (1995) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(95)00001-w · Cited by 97
Treatment of Trypanosoma cruzi-infected children with nifurtimox: a 3 year follow-up by PCR
Solari, A. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.4.515 · Cited by 95
Free radical metabolism of antiparasitic agents.
Docampo, R., & Moreno, S. N. J. (1986) · PubMed · Cited by 93
Lira, R., Contreras, L. M., Rita, R. M. S., et al. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.5.537 · Cited by 90
Guedes, P. M. D. M., Urbina, J. A., de Lana, M., Afonso, L., Veloso, V. M., Tafuri, W. L., Machado-Coelho, G. L. L., Chiari, É., & Bahia, M. T. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.11.4286-4292.2004 · Cited by 86
Population Pharmacokinetics of Benznidazole in Adult Patients with Chagas Disease
Soy, D., Aldasoro, E., Guerrero, L., Posada, E., Serret, N., Mejía, T., Urbina, J. A., & Gascón, J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05018-14 · Cited by 84
Maya, J. D., Repetto, Y., Agosı́n, M., et al. (1997) · Molecular and Biochemical Parasitology · doi:10.1016/s0166-6851(96)02837-x · Cited by 78
In Vitro and in Vivo Effects of Itraconazole against Trypanosoma Cruzi
McCabe, R. E., Remington, J. S., & Araujo, F. G. (1986) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.1986.35.280 · Cited by 73
Sterol composition and biosynthesis in Trypanosoma cruzi amastigotes
Liendo, A., Visbal, G., Piras, M. M., et al. (1999) · Molecular and Biochemical Parasitology · doi:10.1016/s0166-6851(99)00129-2 · Cited by 72
Urbina, J. A., Lira, R., Visbal, G., & Bartrolí, J. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2498-2502.2000 · Cited by 70
Apt, W., Arturo Arribada, C., Zulantay, I., Solari, A., Sánchez, G., Mundaca, K., Coronado, X., Rodríguez, J., Gil, L. C., & Osuna, A. (2005) · Annals of Tropical Medicine and Parasitology · doi:10.1179/136485905x75403 · Cited by 69
Keenan, M., Abbott, M. J., Alexander, P. W., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2015809 · Cited by 68
Gali, W. L., Sarabanda, Á. V. L., Baggio, J. M., Ferreira, L. G., Gomes, G. G., Marin‐Neto, J. A., & Junqueira, L. F. (2014) · EP Europace · doi:10.1093/europace/eut422 · Cited by 64
Progressive Chagas' cardiomyopathy is associated with low selenium levels.
Rivera, M. T., de Souza, A. P., Hasslocher‐Moreno, A. M., Xavier, S. S., Gomes, J. D. A. S., Rocha, M. O. D. C., Corrêa‐Oliveira, R., Nève, J., Vanderpas, J. B., & de Araújo-Jorge, T. C. (2002) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2002.66.706 · Cited by 59
Self-citationNew insights in Chagas disease treatment
Urbina, J. A. (2010) · Drugs of the Future · doi:10.1358/dof.2010.35.5.1484391 · Cited by 52
Two Analogues of Fenarimol Show Curative Activity in an Experimental Model of Chagas Disease
Keenan, M., Chaplin, J. H., Alexander, P. W., Abbott, M. J., Best, W. M., Khong, A., Botero, A., Perez, C. J., Cornwall, S. M. J., Thompson, R. C. A., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401610c · Cited by 49
Pharmacokinetics of Benznidazole in Healthy Volunteers and Implications in Future Clinical Trials
Molina, I., Salvador, F., Sánchez‐Montalvá, A., Artaza, M. A., Moreno, R., Perin, L., Esquisabel, A., Pinto, L., & Pedraz, J. L. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01912-16 · Cited by 49
Self-citationPaniz‐Mondolfi, A., Pérez-Álvarez, A. M., Lanza, G., Márquez, E., & Concepción, J. L. (2009) · Chemotherapy · doi:10.1159/000219436 · Cited by 47
de Castro, A. M., Luquetti, A. O., Rassi, A., et al. (2006) · Parasitology Research · doi:10.1007/s00436-006-0172-5 · Cited by 47
Morilla, M. J., Prieto, M. J., & Romero, E. L. (2005) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/s0074-02762005000200017 · Cited by 24
Cited by
Novel 1, 2, 4‐Triazoles as Antifungal Agents
Kazeminejad, Z., Marzi, M., Shiroudi, A., Kouhpayeh, S. A., Farjam, M., & Zarenezhad, E. (2022) · BioMed Research International · doi:10.1155/2022/4584846 · Cited by 102
Metadata
- Authors
- Sales Junior, P. A., Molina, I., Fonseca Murta, S. M., Sánchez-Montalvá, A., Salvador, F., Corrêa-Oliveira, R., & Carneiro, C. M.
- Venue
- The American Journal of Tropical Medicine and Hygiene
- Published
- 2017-11-08
- Volume
- 97
- Issue
- 5
- Pages
- 1289-1303
- ISSN
- 0002-9637 (ISSN-L)
- 1476-1645
- OpenAlex
- W2763660888
- Cited by
- 305
- References
- 59
- FWCI
- 20.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.